Sabra Healthcare REIT (NASDAQ:SBRA) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• Sabra Healthcare REIT shares moved above their 200-day moving average, reaching $20.82 before closing at $20.61, compared with the average of $20.15.
• Analyst sentiment remains favorable, with seven Buy ratings and six Holds producing a “Moderate Buy” consensus and an average price target of $22.27.
• The company declared a quarterly dividend of $0.30 per share, equal to a 5.8% annualized yield, despite reporting quarterly EPS of negative $0.10—well below the $0.17 estimate—while revenue rose 24.7% year over year.

Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $20.15 and traded as high as $20.82. Sabra Healthcare REIT shares last traded at $20.61, with a volume of 1,607,209 shares traded.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Truist Financial raised their target price on Sabra Healthcare REIT from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Wednesday, July 22nd. Wells Fargo & Company upped their price target on shares of Sabra Healthcare REIT from $22.00 to $23.00 and gave the stock an "overweight" rating in a research report on Monday, June 1st. Scotiabank dropped their price objective on shares of Sabra Healthcare REIT from $22.00 to $19.00 and set a "sector perform" rating on the stock in a report on Thursday, June 18th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Sabra Healthcare REIT in a report on Wednesday, July 22nd. Finally, Citigroup reiterated a "market outperform" rating on shares of Sabra Healthcare REIT in a research report on Wednesday, July 22nd. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $22.27.

Sabra Healthcare REIT Price Performance

The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.07 and a current ratio of 3.07. The firm has a market capitalization of $5.27 billion, a P/E ratio of 79.27, a price-to-earnings-growth ratio of 1.57 and a beta of 0.64. The business has a fifty day moving average of $20.43 and a 200-day moving average of $20.15.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last announced its earnings results on Monday, August 3rd. The real estate investment trust reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.27). Sabra Healthcare REIT had a net margin of 7.61% and a return on equity of 2.34%. The business had revenue of $230.11 million for the quarter, compared to the consensus estimate of $219.39 million. During the same period in the previous year, the firm earned $0.38 EPS. The firm's revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts forecast that Sabra Healthcare REIT, Inc. will post 1.52 EPS for the current fiscal year.

Sabra Healthcare REIT Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 5.8%. The ex-dividend date is Friday, August 14th. Sabra Healthcare REIT's payout ratio is currently 461.54%.

Hedge Funds Weigh In On Sabra Healthcare REIT

Institutional investors and hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth raised its position in shares of Sabra Healthcare REIT by 11.4% during the 1st quarter. Focus Partners Wealth now owns 23,146 shares of the real estate investment trust's stock worth $404,000 after buying an additional 2,375 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Sabra Healthcare REIT by 150.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,555 shares of the real estate investment trust's stock worth $47,000 after acquiring an additional 1,536 shares during the period. First Trust Advisors LP boosted its holdings in shares of Sabra Healthcare REIT by 27.2% in the second quarter. First Trust Advisors LP now owns 368,383 shares of the real estate investment trust's stock valued at $6,793,000 after acquiring an additional 78,709 shares in the last quarter. Cerity Partners LLC boosted its holdings in shares of Sabra Healthcare REIT by 73.0% in the second quarter. Cerity Partners LLC now owns 18,686 shares of the real estate investment trust's stock valued at $345,000 after acquiring an additional 7,885 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in shares of Sabra Healthcare REIT by 3.1% during the second quarter. Daiwa Securities Group Inc. now owns 83,889 shares of the real estate investment trust's stock valued at $1,547,000 after acquiring an additional 2,557 shares during the period. Institutional investors own 99.40% of the company's stock.

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source